UNSPSC 51202404: Canakinumab

This classification denotes a monoclonal antibody with the molecular formula C6452H9958N1722O2010S42, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 37CQ2C7X93, more generally known as canakinumab. European Medicines Agency schedules canakinumab in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB30137. The term CANAKINUMAB is an International Non-Proprietary Name or INN. see WHO INN reference publication, Volume 22, No. 1, 2008, list 59.

As of Q4 2014, CANAKINUMAB remains US FDA's Preferred Term for this commodity.

UNSPSC 51202404 Canakinumab (Commodity) does not align with state and local procurement activity currently posted under this code. The recent opportunities captured in the dataset are for naloxone and drug deactivation systems, direct-to-manufacturer prescription programs, medical and first aid supplies for emergency response, and generic multi-source pharmaceuticals and OTC products—none of which match the specific biologic immunosuppressant indicated by the code name. The mismatch suggests either miscoding at source or that canakinumab does not feature in active state and local solicitation currently tracked in public procurement databases.

The issuing bodies captured in the recent dataset span state health and human services agencies (Texas HHS Commission, Minnesota Department of Administration), county health departments (Seminole County, Florida), municipal fire departments (Tampa Fire Department), and cooperative purchasing alliances serving multi-state government procurement (MMCAP). The geographic spread includes Florida, Texas, Minnesota, and Oregon through cooperative arrangements. Representative recent opportunities include Seminole County's IFB for naloxone and drug deactivation systems (1,900 units naloxone and 800 deactivation systems annually, due July 26, 2023); the City of Tampa's ITB for medical and first aid supplies for its Fire Department Rescue Division (169 line items, estimated $700,000, sheltered for certified Small Local Business Enterprises, due March 13, 2026); MMCAP's RFP for generic multi-source pharmaceuticals and OTC products across member states (due March 26, 2026, awarded May 15, 2026); and the Texas HHS Commission's RFI on direct-to-manufacturer prescription programs (due April 3, 2026). Without active solicitations specifically for canakinumab, this code presents limited pursuit opportunity in the current state and local marketplace.